OKYO Pharma (NASDAQ:OKYO) Receives Sell (D-) Rating from Weiss Ratings

Key Points

• OKYO Pharma has received a Sell (D-) rating from Weiss Ratings, indicating a negative outlook on its stock.
• Several analysts have differing opinions on the stock, with a current overall rating of Hold and an average target price of $7.00.
• OKYO Pharma's shares have increased by 10.3%, opening at $2.24, but it has a significant range, with a 12-month low of $0.90 and a high of $3.35.

OKYO Pharma (NASDAQ:OKYO - Get Free Report)'s stock had its "sell (d-)" rating reiterated by equities researchers at Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.

Several other equities research analysts also recently commented on the company. Zacks Research upgraded OKYO Pharma to a "hold" rating in a report on Tuesday, September 16th. HC Wainwright reaffirmed a "buy" rating and set a $7.00 price target on shares of OKYO Pharma in a research report on Tuesday, September 23rd. Finally, Wall Street Zen upgraded OKYO Pharma to a "hold" rating in a research note on Saturday, August 9th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, OKYO Pharma presently has an average rating of "Hold" and an average target price of $7.00.

OKYO Pharma Trading Up 10.3%

OKYO Pharma stock opened at $2.24 on Wednesday. OKYO Pharma has a 12-month low of $0.90 and a 12-month high of $3.35. The business's 50-day moving average price is $2.39 and its two-hundred day moving average price is $2.08.

Institutional Trading of OKYO Pharma

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Wealth Enhancement Advisory Services LLC bought a new position in OKYO Pharma during the second quarter valued at $28,000. FNY Investment Advisers LLC bought a new stake in shares of OKYO Pharma in the 1st quarter worth about $25,000. Finally, Dauntless Investment Group LLC bought a new stake in shares of OKYO Pharma in the 1st quarter worth about $2,526,000. 2.97% of the stock is owned by hedge funds and other institutional investors.

About OKYO Pharma

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.